Related Experiment Video
Updated: May 17, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Absence of the RET+3:T allele in the MTC patients
Pawel Borun1, Sowinski Jerzy, Katarzyna Ziemnicka
1Institute of Human Genetics Polish Academy Sciences, ul, Strzeszyńska 32, 60-479, Poznan, Poland. andp@man.poznan.pl.
Abstract:
The mutations of the RET proto-oncogene contributes to the development of MTC by increasing the activity of the receptor encoded by this gene. Variant T of polymorphism rs2435357 located in the enhancer of the RET gene reduces the enhancer's activity. The opposite effects of rs2435357 and the mutations causing medullary thyroid carcinoma resulted in the investigation of the status of this polymorphism in patients with MTC. In our study, we compared the frequency of polymorphism rs2435357 in the group of 48 MTC patients with its frequency in Polish population. The frequency of heterozygotes C/T at rs2435357 reached almost 12% (18/152) for the Polish population, in contrast to the group of MTC patients where not even a single T allele was found. The frequency difference is statistically significant. This observation might indicate that the presence of the heterozygous T allele at rs2435357 may be associated with the inhibition of medullary thyroid carcinoma development.
Insights
The T allele of RET gene polymorphism rs2435357 was absent in medullary thyroid carcinoma (MTC) patients, unlike the general Polish population. This suggests the T allele may inhibit MTC development.
Area of Science:
- Genetics
- Oncology
- Molecular Biology
Background:
- The RET proto-oncogene plays a crucial role in medullary thyroid carcinoma (MTC) development, with mutations increasing receptor activity.
- Polymorphism rs2435357 in the RET gene enhancer, specifically the T variant, has been shown to decrease enhancer activity.
Purpose of the Study:
- To investigate the frequency of the rs2435357 polymorphism in Polish medullary thyroid carcinoma patients.
- To explore the potential association between the rs2435357 T allele and the inhibition of MTC development.
Main Methods:
- A case-control study comparing the frequency of the rs2435357 polymorphism in 48 MTC patients against the general Polish population.
- Genotyping analysis to determine the allelic and genotypic frequencies of rs2435357.
Main Results:
- The heterozygous C/T genotype for rs2435357 was observed in nearly 12% of the Polish population (18/152).
- Notably, not a single T allele was detected in the group of 48 MTC patients.
- The observed difference in T allele frequency between MTC patients and the general population was statistically significant.
Conclusions:
- The absence of the T allele in MTC patients suggests a potential protective role.
- The heterozygous T allele at rs2435357 may be associated with the inhibition of medullary thyroid carcinoma development.
Related Concept Videos
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Incomplete Dominance
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of Life
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Non-LTR Retrotransposons

